611
Alternative Names: Anti-IL4Ra antibody; Recombinant humanized anti-IL-4 receptor alpha IgG4 monoclonal antibodyLatest Information Update: 27 Jan 2026
At a glance
- Originator 3SBio
- Developer 3SBio; Sunshine Guojian Pharmaceutical
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis; Chronic obstructive pulmonary disease
- No development reported Eczema
Most Recent Events
- 20 Nov 2025 Sunshine Guojian Pharmaceutical completes a phase III trial for Atopic dermatitis in China (SC, Injection) (NCT06173284)
- 05 Aug 2025 Phase-III clinical trials in Atopic dermatitis (In adolescents) in China (SC) (NCT07042126)
- 16 Jul 2025 Phase-III clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in China (SC) (NCT07039669)